Patient centricity

Almac Diagnostics discusses new biomarker service

Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.

Safety and value driving Phase IV growth at CROs; EVP

Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Follow us

Products

View more

Webinars